Toralf Reimer - Concepedia

Author

Toralf Reimer

Also Known As

A. Sallmann, Angrit Stachs, Birgitte Vrou Offersen, Jean-Marc Classe, Reimer T, Reimer, T., T REIMER, T Reimer, T. Reimer, Thomas Klein

438

Publications

10.6K

Citations

H-Index

132

Concepts

All Affiliations

University of Rostock Klinikum Südstadt Rostock German Breast group Heidelberg University Ludwig-Maximilians-Universität München

About

Toralf Reimer is an author at University of Rostock specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	59	2.8K
2	Health Sciences	16	21	688
3	Engineering	4	4	125
4	Natural Sciences	4	4	122
5	Nursing	2	2	46

Toralf Reimer

122

Publications

8.6K

Citations

H-Index

Page 1

	Year	Citations
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase, Journal of Clinical Oncology	2014	1K
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Carsten Denkert, Fenja Seither, Andreas Schneeweiß, The Lancet Oncology Breast OncologyHer2-low-positive Breast CancerIndividual Patient DataMedicinePathology	2021	533
The Oncological Safety of Skin Sparing Mastectomy with Conservation of the Nipple-Areola Complex and Autologous Reconstruction: An Extended Follow-Up Study Bernd Gerber, Annette Krause, Max Dieterich, Annals of Surgery	2009	391
Skin-Sparing Mastectomy with Conservation of the Nipple–Areola Complex and Autologous Reconstruction is an Oncologically Safe Procedure Bernd Gerber, Annette Krause, Toralf Reimer, Annals of Surgery	2003	387
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment Oleg Gluz, Ulrike Nitz, Matthias Christgen, Journal of Clinical Oncology	2016	357
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial Sibylle Loibl, Frederik Marmé, Miguel Martín, Journal of Clinical Oncology	2021	310
Effect of Luteinizing Hormone–Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study Bernd Gerber, Gϋnter von Minckwitz, H. Stehle, Journal of Clinical Oncology	2011	296
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group Carsten Denkert, Stephan Wienert, Audrey Poterie, Modern Pathology Tumor ImmunologyBreast OncologyCancer ImmunosurveillanceMedicineImmunology	2016	268
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial Jens Huober, Peter A. Fasching, M. Barsoum, The Breast	2011	226
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases Jana de Boniface, Tove Filtenborg Tvedskov, Lisa Rydén, New England Journal of Medicine	2024	208

Page 1